Neighborhood Health Plan of Rhode Island (Neighborhood) develops and maintains Clinical Medical Policies (CMPs) to provide coverage criteria for specific medical technologies, procedures, and treatments. Neighborhood’s CMPs are developed based on a thorough review of current medical literature, standards of care, and to the extent possible, according to evidence-based outcomes. On an annual basis, CMPs are reviewed by Neighborhood’s Clinical Management Committee for reapproval by Neighborhood’s Medical Director.

Neighborhood’s Clinical Management Committee and Medical Director will be reviewing Neighborhood’s CMP for Urine Toxicology Testing (Screening) - # 071 in July 2021.

- In accordance with CMP # 071, immunoassay testing is a covered service if performed at point of service only. Performance of immunoassay urine toxicology testing (screening) in a laboratory setting is not a covered service.

Neighborhood’s Urine Toxicology Testing (Screening) CMP was first approved in June 2016 to provide the most appropriate service and align with industry-recommended practice. This policy does not affect laboratory definitive testing (also known as Quantitative or Confirmatory Testing).

Neighborhood’s CMPs aim to ensure the provision of clinically necessary services at the appropriate level of care for the appropriate duration. The Urine Toxicology Testing (Screening) CMP and all CMPs are available on the www.nhpri.org website. We are grateful for our provider partners and thank you for your continued cooperation and support. Should you have any issues or concerns regarding CMP # 071, please advise Neighborhood’s Medical Director, Dr. Christopher Ottiano by email at COttiano@NHPRI.org.